Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 and Clarithromycin in Ovarian Epithelial Cancer
NCT07341100Phase 2Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in ovarian epithelial cancer, sponsored by Kelun-Biotech. Started Jan 2026; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
ovarian epithelial cancer
Beyond the preview
Go deeper on NCT07341100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07341100.